KarXT, likely to receive the nod from the US FDA by late 2024, will significantly impact the market with the potential to reduce the positive, negative, and cognitive symptoms of schizophrenia.
The long-term data is encouraging, signaling that KarXT is not associated with “burdensome side effects” the major impediments of the current regime.
Schizophrenia, a relapsing life-long illness, like most neuropsychiatric disorders, presents a debilitating human, medical, and socioeconomic burden due to persistent misconceptions and stigma that hinder access to care, timely diagnosis, and consistent treatment. It impairs the perception of reality with variable presenta...
